CURRENT CLINICAL TRIALS

Mercer University Clinical Research Department is proud to offer a large number of clinical trials for patients and potential patients. Our researchers start new trials throughout the year, so the list is updated frequently. For questions regarding a specific clinical trial, please contact the Clinical Research Manager at 478-301-5846, and she will direct you to the appropriate study coordinator.

ENROLLING STUDIES:

- **GS-US-540-9012:** A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting.
- **HEART FID (1VIT15043):** A Randomized, Double Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency
- **JANSSEN – DEFINE:** A Phase 4, Randomized, Active-Controlled, Open-label Study to Evaluate the Safety and Tolerability of Switching to Once-Daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fix-dose Combination (FDC) Regimen in the Virologically suppressed Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Experiencing Rapid Weight Gain in an INI + TAF/FTC ARV Regimen

STUDIES IN FOLLOW UP:

- **GS-US-200-4334:** A phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-Acting Capsid Inhibitor (GS 6207 in Combination with Other Antiretroviral Agents in Patients Living with HIV
- **GS-US-380-1490:** A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
- **GSK-Atlas 2M (207966):** A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1 Adults who are Virologically Suppressed
- **GSK-FLAIR (201584):** A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naïve Adult Participants
- **GSK-POLAR (209035):** A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-I infected Adults who are Virologically Suppressed and Participated in Study LAI116482
- **GSK-TANGO (204862):** A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
- **MK-8591A-018:** A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

MERCER UNIVERSITY
SCHOOL OF MEDICINE